All In Biotech

Drug Trial Radar · NCT05774873

The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.

A Phase I/II Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Aug 9, 2023

Primary completion

Mar 20, 2025

Study completion Mar 20, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • IBI334Drug

    There are six dose of IBI334 ,QW IV in first cycle and Q2W IV behind the first cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment-related adverse eventsTime frame: Up to 60 days post last dose
  2. Percentage of subjects woth Dose-Limitine toxicities(DLTs)Time frame: Up to 28 days following first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated Cancer Hospital of Shandong First Medical university

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.